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Summary Catheter ablation in patients with persistent atrial ﬁbrillation (AF) is challenging.
There are few reports of catheter ablation for persistent AF with persistent left superior vena
cava (PLSVC). We report an ablation case of persistent AF with PLSVC solely guided by complex
fractionated atrial electrogram (CFAE).
The subject was a 65-year-old man. Electroanatomic mapping system was used to integrate
computed tomography data with 3D mapping data. We identiﬁed the CFAE sites on the elec-
troanatomic mapping. Radiofrequency ablation was applied to the CFAE sites; the posterior
aspect of left superior pulmonary vein (LSPV), the anterior ridge of left atrial appendage, and
the roof at the anterior to the LSPV. After those ablations, AF was ﬁnally terminated by ablation
in the middle of the PLSVC.
Previous investigators have reported that pulmonary vein antrum isolation (PVAI) is effec-
tive for the management of patients with either paroxysmal or persistent AF. However, some
patients experience episodes of AF despite successful PVAI, which implies that important trig-
gers and perpetuators remain in the posterior left atrium, crista terminalis, superior vena cava,
coronary sinus ostium, interatrial septum, and the ligament of Marshall/PLSVC. In conclusion,
CFAE ablation was useful in a patient with persistent AF with PLSVC.
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Introduction
Catheter ablation is a useful approach for the manage-
ment of atrial ﬁbrillation (AF) [1—5]. While the pulmonary
veins (PVs) are often the site of ectopic beat genera-
tion in patients with paroxysmal AF [1,6], their role in
persistent AF remains unclear, where initiation and per-
petuation (substrate) may be more important. A variety of
techniques, including linear lesions with PV antrum isola-
tion (PVAI) and/or complex fractionated atrial electrogram
(CFAE)-guided ablation, have been proposed to improve out-
comes in patients with persistent AF [7—12].
A persistent left superior vena cava (PLSVC) is the embry-
ological precursor of the ligament of Marshall, which has
been implicated in the initiation and maintenance of AF
[13—15]. For example, Haïssaguerre et al. suggested that
the PLSVC is one arrhythmogenic source of AF and that the
PLSVC could be isolated from both atria in 4 of 5 patients
[16].
Nademanee et al. recently described a new approach
for AF ablation by identifying the target ‘‘substrate’’ sites
guided by CFAEs [8—10]. This technique achieved a high
rate of success in maintaining sinus rhythm (SR) in patients
with either paroxysmal or persistent AF. However, PVAI alone
appeared to be an ineffective therapy against the AF trigger
and/or AF substrate in PLSVC, thus leading to suboptimal
results. The present report describes a case of a patient
with PLSVC and persistent AF in which CFAE ablation was
successfully employed.
Case report
A 65-year-old man with a history of ablation for atrial ﬂutter
3 years prior was referred for management of symptomatic
persistent AF and PLSVC. Transesophageal echocardiogra-
phy documented absence of thrombus in the left atrial
appendage, while transthoracic echocardiography demon-
strated a left atrial dimension of 43mm, left atrial volume
of 166.7ml, volume index of 84ml/m2, left ventricular
diastolic and systolic dimension of 48/28mm, and ejection
Figure 1 Electroanatomic mapping of the voltage map merged mu
(AP) view (A), and the posteroanterior (PA) view (B). Red dots are ab
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raction of 73%. PLSVC was detected by echocardiography
nd by cardiac multidetector computed tomography (MDCT,
ig. 1). At the time of hospitalization, B-type natriuretic
eptide was elevated at 385 pg/ml, human atrial natriuretic
eptide was 63.6 pg/ml, and thyroid function tests were
ithin normal limits.
Cardiac MDCT was performed to obtain pre-procedural
hree-dimensional (3D) data regarding the anatomy of the
eft atrium (LA), PVs, coronary sinus (CS), and the PLSVC.
fter written informed consent was obtained, the patient
nderwent electrophysiologic study under conscious seda-
ion. Multipolar electrode catheters were positioned in the
sophagus to measure the temperature during the ablation,
nd in the coronary sinus (CS) to the PLSVC via the right
nternal jugular vein. After trans-septal puncture [as guided
y intra-cardiac echocardiography (ICE)], an SL0 sheath (St
ude Medical Inc., St Paul, MN, USA) was introduced trans-
eptally into the LA. High-resolution anatomic information
rom contrast-enhanced cardiac MDCT was reconstructed,
nd the heart chambers were segmented and implemented
n the electroanatomic mapping system (CARTO Merge®,
iosense Webster Inc., Diamond Bar, CA, USA; Fig. 1).
lectroanatomic mapping of the LA and PLSVC was per-
ormed with the use of 7F, 8-mm tip catheter (NAVI-STAR®,
iosense Webster Inc.). A 3D electroanatomic mapping sys-
em was used to integrate MDCT data with 3D mapping
ata.
AF ablation was performed as previously described
8—10], with some modiﬁcation (the speciﬁc irrigation
atheter, CFAE software on CARTO, and ibutilide are
ot available in Japan). Therefore, the present patient
nderwent non-ﬂuoroscopic electroanatomic mapping with
he CARTOTM mapping system (Biosense Webster). Heparin
3000 i.u. bolus and subsequent 1000—2000 i.u. boluses to
eep the activated clotting time >250 s) was administered
or anticoagulation.ltidetector computed tomography, showing the anteroposterior
lation points.
An individualized electroanatomic map was created.
sing a voltage map, tags were placed in the CFAE site to
nable the operator to associate areas of CFAE with both
tria and CS/PLSVC and thereby identify target sites for
blation. Bipolar recordings were ﬁltered at 30—500Hz, and
e156 Y. Iriki et al.
Figure 2 Intra-cardiac electrograms of CFAEs show: (A) CFAEs at the posterior aspect of the LSPV; (B) CFAEs at the termination site
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sn the middle of PLSVC; (C) the termination of AF. CFAEs, comp
ein; PLSVC, persistent left superior vena cava; AF, atrial ﬁbrill
he CFAE was deﬁned as: (1) fractionated electrograms com-
osed of two or more deﬂections, and/or a perturbation of
he baseline with continuous deﬂection of a prolonged acti-
ation complex, and (2) atrial electrograms with a very short
ycle length (≤120ms).
Radiofrequency (RF) applications were delivered with
emperature control and a maximal temperature of 55 ◦C at
he catheter tip (8-mm NaviStar catheters) with a maximal
ower of 50W (LA posterior, in the PLSVC 30W).
The endpoints during RF ablation were either complete
limination of areas with CFAE or transient conversion of
F to SR following injection of nifecarant (0.15mg/kg). If
he arrhythmias were not successfully terminated, external
ardioversion was performed.
esults
fter electroanatomic mapping of the LA and CS/PLSVC was
erformed, CFAE sites in the LA were ablated. RF application
as applied to (1) the posterior aspect of the left superior
ulmonary vein (LSPV), (2) the anterior ridge of left atrial
ppendage (LAA), and (3) the anterior roof of the LA close
o the LSPV. After these ablations, the local electrograms
f LA and CS were not organized and AF persisted. Accord-
ng to the whole mapping of LA, all of the areas of CFAE in
he LA were thought to be completely eliminated. Thus we
a
r
t
gractionated atrial electrograms; LSPV, left superior pulmonary
.
ecided to go to the RF applications into the PLSVC. Finally
F was terminated by ablating the mid-portion of the PLSVC
Figs. 1 and 2).
Procedural time was 5 h 26min, and the ﬂuoroscopic time
as 58min. The radiofrequency duration was 75min, and
adiofrequency was applied at 157 points.
The patient remained in sinus rhythm at 12 months after
blation.
iscussion
revious investigators have reported that PVAI is an effective
trategy for the management of patients with either parox-
smal or persistent AF [4—12]. However, some patients still
xperience episodes of AF despite successful isolation of the
VA, which implies that important triggers and perpetuators
emain in the posterior left atrium, crista terminalis, supe-
ior vena cava, coronary sinus ostium, interatrial septum,
nd the ligament of Marshall/PLSVC [5,6]. Thus, the present
tudy utilized CFAE-guided ablation to eliminate the sub-
trate (e.g. the PLSVC). Indeed, AF was terminated through
blation of the PLSVC following ablation of the LA.
The efﬁcacy of the CFAE-guided catheter ablation
emains controversial [8—11]. Further studies are required
o characterize the efﬁcacy and suitability of ablation solely
uided by CFAE.
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Limitations
This is the third case of CFAE-guided ablation and the ﬁrst
case of CFAE ablation of persistent AF that has been per-
formed in Japan. The ﬂuoroscopic time and procedural
time was much longer than that described in other coun-
tries. Since ibutilide is not available in Japan, nifekalant,
0.15mg/kg over 5min (the conventional nifekalant dose of
0.30mg/kg was not used in order to avoid terminating the
AF by chemical means) was used to increase the AF cycle
length (CL) and to highlight the CFAE site. However, the CL
increased by only 5%, and the drug was injected 1 h before
termination of the arrhythmia. Since the drug’s half-life
is approximately 90min (in contrast to ibutilide, in which
the half-life is approximately 6 h), it is unlikely that use of
nifekalant resulted in termination of AF.
Conclusion
This case demonstrates a role for PLSVC in the maintenance
of AF as well as the efﬁcacy of CFAE-guided ablation in a
patient with persistent AF and PLSVC.
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